GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pyxis Oncology Inc (NAS:PYXS) » Definitions » PS Ratio

Pyxis Oncology (Pyxis Oncology) PS Ratio : 11.56 (As of Jun. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pyxis Oncology PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Pyxis Oncology's share price is $3.64. Pyxis Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.32. Hence, Pyxis Oncology's PS Ratio for today is 11.56.

The historical rank and industry rank for Pyxis Oncology's PS Ratio or its related term are showing as below:

PYXS' s PS Ratio Range Over the Past 10 Years
Min: 11.37   Med: 13.43   Max: 17.33
Current: 11.52

During the past 5 years, Pyxis Oncology's highest PS Ratio was 17.33. The lowest was 11.37. And the median was 13.43.

PYXS's PS Ratio is ranked worse than
55.8% of 1000 companies
in the Biotechnology industry
Industry Median: 9.29 vs PYXS: 11.52

Pyxis Oncology's Revenue per Sharefor the three months ended in Mar. 2024 was $0.32. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.32.

Back to Basics: PS Ratio


Pyxis Oncology PS Ratio Historical Data

The historical data trend for Pyxis Oncology's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pyxis Oncology PS Ratio Chart

Pyxis Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
- - - - -

Pyxis Oncology Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 13.52

Competitive Comparison of Pyxis Oncology's PS Ratio

For the Biotechnology subindustry, Pyxis Oncology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pyxis Oncology's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pyxis Oncology's PS Ratio distribution charts can be found below:

* The bar in red indicates where Pyxis Oncology's PS Ratio falls into.



Pyxis Oncology PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Pyxis Oncology's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=3.64/0.315
=11.56

Pyxis Oncology's Share Price of today is $3.64.
Pyxis Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.32.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Pyxis Oncology  (NAS:PYXS) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Pyxis Oncology PS Ratio Related Terms

Thank you for viewing the detailed overview of Pyxis Oncology's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pyxis Oncology (Pyxis Oncology) Business Description

Traded in Other Exchanges
N/A
Address
150 Cambridgepark Drive, Cambridge, MA, USA, 02140
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its lead ADC product candidate is PYX-201, an investigational human IgG1 isotype site-specifically conjugated with an auristatin toxin targeting EDB that initially develop for solid tumors, including NSCLC, hormone receptor-positive breast, ovarian and thyroid cancer. The IO product candidate is PYX-106, designed to block Siglec-15-mediated suppression of T-cell proliferation and function.
Executives
Pamela Ann Connealy officer: Chief Financial Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Jitendra Wadhane officer: Chief Accounting Officer 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Lara Sullivan director, officer: Chief Executive Officer C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Jakob Dupont director C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Pfizer Inc 10 percent owner 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Pfizer Ventures (us) Llc 10 percent owner 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Rachel Humphrey director C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Mark Chin other: Former Director 20 BERKELEY SQUARE, MAYFAIR, LONDON X0 W1J 6EQ
Darren S Cline director 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Thomas Civik director C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bayer World Investments B.v. 10 percent owner ENERGIEWEG 1, MIJDRECHT P7 3641
Freda C Lewis-hall director C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Ronald Herbst officer: Chief Scientific Officer 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140